Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 3.57
MR's Cash to Debt is ranked higher than
78% of the 288 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.07 vs. MR: 3.57 )
MR' s 10-Year Cash to Debt Range
Min: 0.65   Max: No Debt
Current: 3.57

Equity to Asset 0.66
MR's Equity to Asset is ranked higher than
76% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. MR: 0.66 )
MR' s 10-Year Equity to Asset Range
Min: 0.32   Max: 0.89
Current: 0.66

0.32
0.89
Interest Coverage 33.13
MR's Interest Coverage is ranked higher than
71% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 32.42 vs. MR: 33.13 )
MR' s 10-Year Interest Coverage Range
Min: 17.97   Max: 9999.99
Current: 33.13

17.97
9999.99
F-Score: 6
Z-Score: 4.37
M-Score: -2.60
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 14.94
MR's Operating margin (%) is ranked higher than
86% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.64 vs. MR: 14.94 )
MR' s 10-Year Operating margin (%) Range
Min: 17.32   Max: 27.61
Current: 14.94

17.32
27.61
Net-margin (%) 16.75
MR's Net-margin (%) is ranked higher than
93% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.64 vs. MR: 16.75 )
MR' s 10-Year Net-margin (%) Range
Min: 17   Max: 26.52
Current: 16.75

17
26.52
ROE (%) 14.59
MR's ROE (%) is ranked higher than
88% of the 278 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.72 vs. MR: 14.59 )
MR' s 10-Year ROE (%) Range
Min: 14.57   Max: 128.45
Current: 14.59

14.57
128.45
ROA (%) 9.31
MR's ROA (%) is ranked higher than
88% of the 289 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.87 vs. MR: 9.31 )
MR' s 10-Year ROA (%) Range
Min: 10.31   Max: 85.21
Current: 9.31

10.31
85.21
ROC (Joel Greenblatt) (%) 48.64
MR's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 288 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.54 vs. MR: 48.64 )
MR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 45.32   Max: 227.92
Current: 48.64

45.32
227.92
Revenue Growth (3Y)(%) 19.10
MR's Revenue Growth (3Y)(%) is ranked higher than
92% of the 262 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.50 vs. MR: 19.10 )
MR' s 10-Year Revenue Growth (3Y)(%) Range
Min: 15.5   Max: 55.9
Current: 19.1

15.5
55.9
EBITDA Growth (3Y)(%) 13.80
MR's EBITDA Growth (3Y)(%) is ranked higher than
84% of the 220 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.30 vs. MR: 13.80 )
MR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 62.4
Current: 13.8

0
62.4
EPS Growth (3Y)(%) 12.30
MR's EPS Growth (3Y)(%) is ranked higher than
79% of the 219 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.20 vs. MR: 12.30 )
MR' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 63
Current: 12.3

0
63
» MR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

MR Guru Trades in Q4 2013

Frank Sands 6,155 sh (New)
John Rogers 33,088 sh (New)
Matthews China Fund 998,168 sh (+2.84%)
John Hussman 22,500 sh (unchged)
Jim Simons Sold Out
Manning & Napier Advisors, Inc 4,627,432 sh (-17.83%)
Robert Karr 656,715 sh (-67.4%)
» More
Q1 2014

MR Guru Trades in Q1 2014

Jim Simons 212,150 sh (New)
Frank Sands 433,390 sh (+6941.27%)
John Rogers 56,448 sh (+70.6%)
John Hussman 22,500 sh (unchged)
Matthews China Fund 998,168 sh (unchged)
Robert Karr Sold Out
Manning & Napier Advisors, Inc Sold Out
» More
Q2 2014

MR Guru Trades in Q2 2014

Jim Simons 400,500 sh (+88.78%)
John Rogers 76,981 sh (+36.38%)
Frank Sands 463,790 sh (+7.01%)
Matthews China Fund 998,168 sh (unchged)
John Hussman Sold Out
» More
Q3 2014

MR Guru Trades in Q3 2014

Frank Sands 485,275 sh (+4.63%)
John Rogers 78,349 sh (+1.78%)
Matthews China Fund 950,168 sh (-4.81%)
Jim Simons 274,100 sh (-31.56%)
» More
» Details

Insider Trades

Latest Guru Trades with MR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2014-06-30 Sold Out 0.06%$30.1 - $34.4 $ 26.87-15%0
John Rogers 2014-06-30 Add 36.38%0.01%$30.1 - $34.4 $ 26.87-15%76981
Robert Karr 2014-03-31 Sold Out 1.6%$30.41 - $40.2 $ 26.87-23%0
Frank Sands 2014-03-31 Add 6941.27%0.04%$30.41 - $40.2 $ 26.87-23%433390
John Rogers 2014-03-31 Add 70.6%0.01%$30.41 - $40.2 $ 26.87-23%56448
Robert Karr 2013-12-31 Reduce -67.4%3.98%$35.61 - $42.07 $ 26.87-31%656715
John Rogers 2013-12-31 New Buy0.02%$35.61 - $42.07 $ 26.87-31%33088
Frank Sands 2013-12-31 New Buy$35.61 - $42.07 $ 26.87-31%6155
Robert Karr 2013-09-30 Reduce -10.38%0.75%$36.89 - $43.74 $ 26.87-33%2014532
Robert Karr 2013-06-30 New Buy7.2%$36.43 - $41.71 $ 26.87-32%2247881
John Hussman 2012-06-30 Add 350%0.01%$28.6 - $33.61 $ 26.87-15%22500
Daniel Loeb 2011-12-31 Sold Out 0.31%$23.71 - $28.06 $ 26.875%0
John Hussman 2011-12-31 Add 150%$23.71 - $28.06 $ 26.875%5000
Robert Karr 2011-09-30 Sold Out 1.7631%$21.36 - $28.29 $ 26.876%0
Daniel Loeb 2011-09-30 New Buy0.31%$21.36 - $28.29 $ 26.876%275000
George Soros 2011-09-30 Sold Out 0.1085%$21.36 - $28.29 $ 26.876%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 14.70
MR's P/E(ttm) is ranked higher than
94% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 41.40 vs. MR: 14.70 )
MR' s 10-Year P/E(ttm) Range
Min: 14.68   Max: 95.74
Current: 14.7

14.68
95.74
P/B 2.06
MR's P/B is ranked higher than
81% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.52 vs. MR: 2.06 )
MR' s 10-Year P/B Range
Min: 2.06   Max: 13.78
Current: 2.06

2.06
13.78
P/S 2.45
MR's P/S is ranked higher than
73% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.80 vs. MR: 2.45 )
MR' s 10-Year P/S Range
Min: 2.45   Max: 25.84
Current: 2.45

2.45
25.84
PFCF 16.59
MR's PFCF is ranked higher than
94% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 56.61 vs. MR: 16.59 )
MR' s 10-Year PFCF Range
Min: 15.03   Max: 130
Current: 16.59

15.03
130
EV-to-EBIT 13.07
MR's EV-to-EBIT is ranked higher than
92% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.95 vs. MR: 13.07 )
MR' s 10-Year EV-to-EBIT Range
Min: 13.2   Max: 98.2
Current: 13.07

13.2
98.2
PEG 1.43
MR's PEG is ranked higher than
95% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. MR: 1.43 )
MR' s 10-Year PEG Range
Min: 0.39   Max: 2.35
Current: 1.43

0.39
2.35
Shiller P/E 17.57
MR's Shiller P/E is ranked higher than
94% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 143.42 vs. MR: 17.57 )
MR' s 10-Year Shiller P/E Range
Min: 17.56   Max: 42.2
Current: 17.57

17.56
42.2
Current Ratio 3.16
MR's Current Ratio is ranked higher than
79% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.72 vs. MR: 3.16 )
MR' s 10-Year Current Ratio Range
Min: 1.52   Max: 6.71
Current: 3.16

1.52
6.71
Quick Ratio 2.78
MR's Quick Ratio is ranked higher than
82% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.85 vs. MR: 2.78 )
MR' s 10-Year Quick Ratio Range
Min: 1.28   Max: 6.24
Current: 2.78

1.28
6.24

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.90
MR's Dividend Yield is ranked higher than
65% of the 149 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.45 vs. MR: 1.90 )
MR' s 10-Year Dividend Yield Range
Min: 0.34   Max: 2.02
Current: 1.9

0.34
2.02
Dividend Payout 0.27
MR's Dividend Payout is ranked higher than
88% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. MR: 0.27 )
MR' s 10-Year Dividend Payout Range
Min: 0.52   Max: 1.67
Current: 0.27

0.52
1.67
Dividend growth (3y) 42.20
MR's Dividend growth (3y) is ranked higher than
98% of the 111 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.40 vs. MR: 42.20 )
MR' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 42.2
Current: 42.2

0
42.2
Yield on cost (5-Year) 8.21
MR's Yield on cost (5-Year) is ranked higher than
96% of the 152 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.63 vs. MR: 8.21 )
MR' s 10-Year Yield on cost (5-Year) Range
Min: 1.47   Max: 8.73
Current: 8.21

1.47
8.73
Share Buyback Rate -0.70
MR's Share Buyback Rate is ranked higher than
81% of the 234 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.30 vs. MR: -0.70 )
MR' s 10-Year Share Buyback Rate Range
Min: 0   Max: -11
Current: -0.7

Valuation & Return

vs
industry
vs
history
Price/Net Cash 17.01
MR's Price/Net Cash is ranked higher than
90% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. MR: 17.01 )
MR' s 10-Year Price/Net Cash Range
Min: 10.34   Max: 556.33
Current: 17.01

10.34
556.33
Price/Net Current Asset Value 7.59
MR's Price/Net Current Asset Value is ranked higher than
90% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. MR: 7.59 )
MR' s 10-Year Price/Net Current Asset Value Range
Min: 6.12   Max: 186.13
Current: 7.59

6.12
186.13
Price/Tangible Book 3.03
MR's Price/Tangible Book is ranked higher than
81% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.62 vs. MR: 3.03 )
MR' s 10-Year Price/Tangible Book Range
Min: 3.29   Max: 17.44
Current: 3.03

3.29
17.44
Price/DCF (Projected) 0.96
MR's Price/DCF (Projected) is ranked higher than
95% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.67 vs. MR: 0.96 )
MR' s 10-Year Price/DCF (Projected) Range
Min: 1.07   Max: 54.36
Current: 0.96

1.07
54.36
Price/Median PS Value 0.55
MR's Price/Median PS Value is ranked higher than
95% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.19 vs. MR: 0.55 )
MR' s 10-Year Price/Median PS Value Range
Min: 0.62   Max: 4.07
Current: 0.55

0.62
4.07
Price/Peter Lynch Fair Value 1.73
MR's Price/Peter Lynch Fair Value is ranked higher than
94% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. MR: 1.73 )
MR' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.7   Max: 2.18
Current: 1.73

0.7
2.18
Price/Graham Number 1.38
MR's Price/Graham Number is ranked higher than
93% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.76 vs. MR: 1.38 )
MR' s 10-Year Price/Graham Number Range
Min: 1.54   Max: 6.61
Current: 1.38

1.54
6.61
Earnings Yield (Greenblatt) 7.70
MR's Earnings Yield (Greenblatt) is ranked higher than
91% of the 285 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.70 vs. MR: 7.70 )
MR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1   Max: 7.6
Current: 7.7

1
7.6
Forward Rate of Return (Yacktman) 14.03
MR's Forward Rate of Return (Yacktman) is ranked higher than
82% of the 167 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.14 vs. MR: 14.03 )
MR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0.7   Max: 51.4
Current: 14.03

0.7
51.4

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:G2N.Germany, MRN.Mexico,
Mindray Medical International Ltd was incorporated as an exempted company with limited liability in the Cayman Islands on June 10, 2005 under the Companies Law of the Cayman Islands. The Company is a developer, manufacturer and marketer of medical devices worldwide. The Company operates three primary business segments: patient monitoring and life support products, in-vitro diagnostic products, and medical imaging systems. The Company's patient monitoring devices track the physiological parameters of patients, such as heart rate, blood pressure, respiration and temperature. It currently offers patient monitoring devices that are suitable for adult, pediatric and neonatal patients and are used principally in hospital intensive care units, operating rooms and emergency rooms. Its product line offers customers functionality, such as single- and multiple-parameter monitors, mobile and portable multifunction monitors, central stations that can collect and display multiple patient data on a single screen, and an electro-cardiogram monitoring device. Its multi-parameter monitoring devices can be networked, allowing hospitals to remotely gather patient data from patient rooms and centralize that data in a single location. Its patient monitoring devices also have built-in recorders and have batteries for portability in models, as well as power backup in the event of power failure in mobile models. It also offers a line of veterinary monitoring devices. The Life support products offers anesthesia machines, defibrillators, surgical equipment (including surgical beds and surgical lights ceiling pendants), syringes and infusion pumps, as well as ventilators. The in-vitro diagnostic products provide data and analysis on blood, urine and other bodily fluid samples for clinical diagnosis and treatment. It offers a range of semi-automated and fully-automated in-vitro diagnostic products for laboratories, clinics and hospitals to perform analysis to detect and quantify various substances in the patient samples. Its current product portfolio consists of in-vitro diagnostic products in six product categories: hematology analysis products, biochemistry analysis products, immunoassay products, coagulation analysis products, urine sediment analysis products, and microbiology analysis products. The hematology analyzers test blood samples to detect abnormalities or foreign substances. The biochemistry analyzers measure the concentration or activity of substances such as enzymes, proteins and substrates. The immunoassay analyzers measure the concentration of protein such as hormone, tumor marker and virus protein. The coagulation analyzers are used to measure activated partial thromboplastin time (APPT), prothrombin time (PT), thrombin time (TT), fibrinogen (FIB), D-Dimer and clotting factor. Urinalysis includes urine sediment and dry chemistry analysis. Urinalysis, together with hematology and biochemistry analysis, are the three common methods used in in
» More Articles for MR

Headlines

Articles On GuruFocus.com
Matthews China Fund's Top Second Quarter Holdings Jul 31 2014 
Guru Held International Stocks Near 52-Week Lows Jul 31 2014 
Morning Coffee: Widely Held International Guru Stocks Near 52-Week Lows May 16 2014 
The Matthews China Fund's Top Five Fourth Quarter Holdings Feb 04 2014 
12 Healthcare Dividend Stocks With Highest Short Float Ratio Jun 02 2012 
value May 05 2012 
12 Healthcare Dividend Stocks with Gaining Earnings Momentum Apr 02 2012 
5 Mid-Cap Healthcare Dividend Stocks with Perfect Earnings Growth Dec 05 2011 
growth,high ROA,medi Oct 29 2011 
100 Best Growth Stocks – Part VII May 12 2011 

More From Other Websites
China’s medical monitor market leader Mindray controls 37% of the market Dec 14 2014
Mindray Announced Shareholder Resolutions Post 2014 Annual General Meeting Dec 12 2014
Mindray Announced Shareholder Resolutions Post 2014 Annual General Meeting Dec 12 2014
American Biotech Start-Ups Head To China For Capital Partners Nov 24 2014
Mindray to Hold Annual General Meeting in Hong Kong on December 10, 2014 Nov 13 2014
Mindray to Hold Annual General Meeting in Hong Kong on December 10, 2014 Nov 13 2014
Mindray Medical Q3 Earnings in Line, 2014 View Lowered Nov 04 2014
Mindray Medical International Ltd Earnings Call scheduled for 8:00 am ET today Nov 04 2014
Mindray Announces Third Quarter 2014 Financial Results Nov 03 2014
Mindray Announces Third Quarter 2014 Financial Results Nov 03 2014
Q3 2014 Mindray Medical International Ltd Earnings Release - After Market Close Nov 03 2014
Mindray Medical to Exhibit New Products at Upcoming Medical Equipment Fairs Oct 15 2014
Mindray Medical to Exhibit New Products at Upcoming Medical Equipment Fairs Oct 15 2014
Mindray to Report Third Quarter 2014 Financial Results on Nov 3, 2014 Oct 14 2014
The Zacks Analyst Blog Highlights: Yingli Green Energy Holding, JD.com, Mindray Medical... Sep 24 2014
Top Foreign Stock Funds Sep 17 2014
Quality Exams at Your Fingertips Sep 17 2014
Mindray Medical Down to Strong Sell on Weak Q2 Sep 09 2014
The Zacks Analyst Blog Highlights: ReneSola, eLong, China Unicom Hong Kong, Mindray Medical... Aug 15 2014
Mindray Medical Beats Q2 Earnings by a Penny, Cuts 2014 View Aug 12 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK